Atreca to Present at Upcoming Investor Conferences
08 November 2022 - 08:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it will present at the following upcoming conferences:
Cowen 6th Annual IO
Next SummitNovember 11, 2022Fireside Chat: 2:40-3:00 am
EST, November 11, 2022
Stifel Healthcare ConferenceNovember 15-16,
2022Fireside Chat: 8:00-8:30 am EST, November 15, 2022
Evercore ISI HealthCONx ConferenceNovember 29 -
December 1, 2022Fireside Chat: 9:40-10:00 am EST, December 1,
2022
Live webcasts of the presentations can be accessed through the
Events & Presentations section of the Company's website at
http://ir.atreca.com. An archived replay of each presentation will
be available on the Company's website for 30 days following the
live broadcast.
About Atreca, Inc.Atreca is a biopharmaceutical
company developing novel antibody-based immunotherapeutics
generated by its differentiated discovery platform. Atreca's
platform allows access to an unexplored landscape in oncology
through the identification of unique antibody-target pairs
generated by the human immune system during an active immune
response against tumors. These antibodies provide the basis for
first-in-class therapeutic candidates, such as our lead product
candidate ATRC-101, a monoclonal antibody targeting a novel
ribonucleoprotein complex, as well as ATRC-301, an antibody drug
conjugate targeting a novel epitope on EphA2. A Phase 1b study
evaluating ATRC-101 in multiple solid tumor cancers is currently
enrolling patients, and ATRC-301 is in IND-enabling studies. For
more information on Atreca, please visit www.atreca.com.
Forward-Looking StatementsThis release contains
statements regarding matters that are not historical facts that are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, statements regarding
our strategy and future plans, including statements regarding the
development of ATRC-101, ATRC-301, and our preclinical and clinical
plans and the timing thereof. Our actual results may differ
materially from those indicated in these forward-looking statements
due to risks and uncertainties related to the initiation, timing,
progress and results of our research and development programs,
preclinical studies, clinical trials, regulatory submissions, and
other matters that are described in our most recent Annual Report
on Form 10-K and Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) and available on the SEC's
website at www.sec.gov, including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Julia Fuller, 858-692-2001Julia@fordhutmanmedia.com
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Oct 2023 to Nov 2023
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Nov 2022 to Nov 2023